In addition to 123I and 131I, Wang et al.88utilized 125I-labeled Zolbertuximab to evaluate its specific binding affinity for CLDN18.2 and its potential in gastric cancer theranostics. The gene discussed is CLDN18; the disease is gastric cancer.